Literature DB >> 34481037

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.

J Remon1, J-C Soria2, S Peters3.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34481037     DOI： 10.1016/j.annonc.2021.08.1994

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

1.  Analysis of Protein-Protein Interactions Identifies NECTIN2 as a Target of N,N-Bis (5-Ethyl-2-hydroxybenzyl) Methylamine for Inhibition of Lung Cancer Metastasis.

Authors:  Sunisa Thongsom; Nithikoon Aksorn; Korrakod Petsri; Sittiruk Roytrakul; Nicharat Sriratanasak; Worawat Wattanathana; Pithi Chanvorachote
Journal:  Cancer Genomics Proteomics       Date:  2022 Sep-Oct       Impact factor: 3.395

Review 2.  Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature.

Authors:  Sara Franzi; Giovanni Mattioni; Erika Rijavec; Giorgio Alberto Croci; Davide Tosi
Journal:  J Clin Med       Date:  2022-05-07       Impact factor: 4.964

3.  Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy.

Authors:  Tereza Losmanova; Philipp Zens; Amina Scherz; Ralph A Schmid; Mario P Tschan; Sabina Berezowska
Journal:  Cells       Date:  2021-10-13       Impact factor: 6.600

4.  Model Calibration of Pharmacokinetic-Pharmacodynamic Lung Tumour Dynamics for Anticancer Therapies.

Authors:  Maria Ghita; Charlotte Billiet; Dana Copot; Dirk Verellen; Clara Mihaela Ionescu
Journal:  J Clin Med       Date:  2022-02-15       Impact factor: 4.241

Review 5.  Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer-A Review.

Authors:  Krisztian Süveg; Ludwig Plasswilm; Thomas Iseli; Pawel Leskow; Galina Farina Fischer; Paul Martin Putora
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

Review 6.  Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Toon Allaeys; Lawek Berzenji; Patrick Lauwers; Suresh Krishan Yogeswaran; Jeroen M H Hendriks; Charlotte Billiet; Charlotte De Bondt; Paul E Van Schil
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

7.  Lymph but Not Blood Vessel Invasion Is Independent Prognostic in Lung Cancer Patients Treated by VATS-Lobectomy and Might Represent a Future Upstaging Factor for Early Stages.

Authors:  Melanie Biesinger; Nele Eicken; Alexander Varga; Michael Weber; Milos Brndiar; Georg Erd; Peter Errhalt; Klaus Hackner; Sarah Hintermair; Alexander Petter-Puchner; Axel Scheed; Elisabeth Stubenberger; Bahil Ghanim
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

Review 8.  Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses.

Authors:  Pedro Barrios-Bernal; Zyanya Lucia Zatarain-Barrón; Norma Hernández-Pedro; Mario Orozco-Morales; Alejandra Olivera-Ramírez; Federico Ávila-Moreno; Ana Laura Colín-González; Andrés F Cardona; Rafael Rosell; Oscar Arrieta
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-24

9.  The pattern of lymph node metastasis in peripheral pulmonary nodules patients and risk prediction models.

Authors:  Lei Ke; Honghai Ma; Qingyi Zhang; Yiqing Wang; Pinghui Xia; Li Yu; Wang Lv; Jian Hu
Journal:  Front Surg       Date:  2022-08-09

Review 10.  Updated Prognostic Factors in Localized NSCLC.

Authors:  Simon Garinet; Pascal Wang; Audrey Mansuet-Lupo; Ludovic Fournel; Marie Wislez; Hélène Blons
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.